Boustead Singapore's (SGX:F9D) real estate solutions division business secured a major design-and-build contract for an integrated pharmaceutical manufacturing and R&D facility situated within Tuas Biomedical Park, Singapore, according to a Friday filing with the Singapore Exchange.
The project is expected to complete by the third quarter of 2026 and takes the real estate solutions division's order backlog to SG$249 million and the group's engineering order backlog to SG$428 million, the filing said.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。